Imunon, Inc. · NASDAQ:IMNN

Imunon — Chardan's 6th Annual Genetic Medicines Conference 2022

30 slides from Imunon's conference presentation, Oct 3, 2022

  1. Slide 1: Corporate Presentation

    Corporate Presentation Nasdaq: IMNN Chardan’s 6th Annual Genetic Medicines Conference October 3-4, 2022 © 2022 IMUNON Inc. PAGE 1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation and any statements made during any presentation or meeting contain forward-looking statements related to Imunon, Inc. (“Imunon”) under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks an

  3. Slide 3: Developing new medicines that harness the building blocks of life

    • Leveraging innovative plasmid DNA platforms with proprietary synthetic delivery systems and multiple potential indications • Initial clinical focus is on immuno-oncology and infectious Developing new diseases medicines that • Phase II trial underway with GEN-1 (IL-12 immunotherapy) for the localiz

  4. Slide 4: Experienced Management Team

    Experienced Management Team Corinne Le Goff, PharmD Nicholas Borys, MD Khursheed Anwer, PhD Jeffrey W. Church Anthony Recupero, PhD MBA President, CEO and Executive Vice President and MBA Executive Vice President Executive Vice President, CFO Vice President Director Chief Medical Officer and Chief S

  5. Slide 5: Proprietary DNA Plasmid Platforms Encoding for a Variety of Proteins

    Proprietary DNA Plasmid Platforms Encoding for a Variety of Proteins: cytokines, enzymes, mAb, antigens… TheraPlas® PLACCINE® • Polymeric Nanoparticle Delivers DNA Plasmids Coding for • DNA Plasmid vectors engineered for next generation Therapeutic Proteins vaccine technology and delivered with a sy

  6. Slide 6: Imunon's Pipeline of DNA-based Transformative Medicines

    Imunon’s Pipeline of DNA-based Transformative Medicines Platform Program Indication(s) Discovery IND enabling Phase 1 Phase 2 Advanced Ovarian, IL-12 (OVATION) Intraperitoneal (IP) Fallopian Tube or Primary GEN-1 Peritoneal Cancer Advanced Ovarian, IL-12 IP in combination TheraPlas Fallopian Tube or

  7. Slide 7: GEN-1 IL-12 Immuno-Oncology Program

    GEN-1 IL-12 IMMUNO-ONCOLOGY PROGRAM © 2022 IMUNON Inc. PAGE 7

  8. Slide 8: IL-12: A Powerful Immune-Modulating Agent

    IL-12: A Powerful Immune-Modulating Agent Interleukin-12 Can Induce Anti-cancer Immunity Through Multiple Mechanisms Stimulates the proliferation of CD-8 positive T-cells and natural Activation/Proliferation killer (NK) cells and their cytotoxic activity against the tumor Shifts the differentiation

  9. Slide 9: First Target: Ovarian Cancer

    First Target: Ovarian Cancer Epithelial ovarian cancer (EOC) is insidious and usually diagnosed late at an advanced stage. Though EOC initially responds to treatment, the recurrence rate is high. Recent treatments delay progression but overall survival has not improved. Hence there is a need for eff

  10. Slide 10: GEN-1 Targets the Micro-Environment of Ovarian Cancer

    GEN-1 Targets the Micro-Environment of Ovarian Cancer Local production of safe and durable levels of a powerful anti-cancer immune agent, IL-12 GEN-1 Intracavity infusion of GEN-1 has demonstrated durable and local expression of IL-12 in the peritoneum No supraphysiological increases in IL-12 common

  11. Slide 11: GEN-1 has the potential to play a key role in new combination strategies

    As an Immuno-oncology Agent, GEN-1 has the potential to play a key role in new combination strategies Diagnosis: Stages II to IV Debulking surgery NACT in frail patients w/extensive disease GEN-1 Induction therapy (1L) Interval Debulking Surgery (IDS) Platinum-Taxanes chemotherapy +/- bevacizumab, +

  12. Slide 12: GEN-1 OVATION 2 Ovarian Cancer Study

    GEN-1 OVATION 2 Ovarian Cancer Study To Determine Efficacy and Biological Activity With NAC in Stage III/IV Patients 1 : 1 Randomization Added Control Arm to OVATION 2 Newly Diagnosed Neoadjuvant Chemotherapy (NACT) Interval Debulking Adjuvant Chemotherapy Ovarian Cancer + Surgery + Tissue Collectio

  13. Slide 13: GEN-1 OVATION 2 Ovarian Cancer Study: Interim Data

    GEN-1 OVATION 2 Ovarian Cancer Study Interim Data Suggest that GEN-1 is Safe and Active Phase I/II Open Label Trial Interim Data (50% of events) NACT ONLY NACT + GEN-1 • Phase I Portion (N=14) Completed Interval Debulking Surgery (n=70) 56% 68% R0 Resection Rate • 100 mg/m² GEN-1 Dose Confirmed Medi

  14. Slide 14: Interim Data in BRCA-/HRP

    GEN-1 OVATION 2 Ovarian Cancer Study: Interim Data in BRCA-/HRP Greatest Medical Need Targeted Therapy Approach HRP (homologous recombination proficient with no BRCA 1/2 mutations)  Median time to progression is about 9 months  About 45% of ovarian cancer patients are not getting a clinical benefi

  15. Slide 15: Enhancement of Avastin Activity in Ovarian Cancer by GEN-1

    Enhancement of Avastin® Antiangiogenic Agent Activity in Ovarian Cancer by GEN-1 SKOV-3 Ovarian Cancer in Nude Mice Key Rationale for Combination of GEN-1 with Avastin® 90 Control 80 mGEN-1 • Synergistic efficacy potential 70 Avastin (low/med/high) mGEN-1 + Avastin (low/med/high) of VEGF level reduc

  16. Slide 16: New Phase 2 Study in Combination with bevacizumab

    New Phase 2 Study in Combination with bevacizumab Avastin (BEV) + GEN-1 Study Design in Advanced Epithelial Ovarian Cancer. Accepted by the FDA. IDS SLL Maintenance N=50 from 4 sites Pac/Carbo x 4-6 Pac/Carbo x 3 BEV BEV x 2 BEV x 2 PARPi (HRD only) Neoadjuvant Chemotherapy R NACT 1:1 Pac/Carbo x 4-

  17. Slide 17: New Phase 1/2 Study in Combination with Immune Checkpoint Inhibitors

    New Phase 1/2 Study in Combination with Immune Checkpoint Inhibitors ICI/GEN-1 Study Design in Advanced Epithelial Ovarian Cancer. Accepted by the FDA. Phase 1: 3+3 dose escalation (n=12-24) Recurrent Ovarian Cancer GEN-1 (dose escalation) 60, 80 and 100 mg/m2 IP q 2wks Nivolumab 240 mg q 2 wks Ipil

  18. Slide 18: PLACCINE SARS-CoV-2 Proof of Concept

    PLACCINE SARS-CoV-2 PROOF OF CONCEPT P R O P H Y L AC T I C VAC C I N E S PROGRAM © 2022 IMUNON Inc. PAGE 18

  19. Slide 19: PLACCINE Platform: Powering the Next Generation of Vaccines

    PLACCINE Platform: Powering the Next Generation of Vaccines By addressing the shortcomings of current nucleic acid, viral vector and protein subunit vaccines Multicistronic pDNA Synthetic Nanoparticles Expression Vector Delivery Systems Complexes + Antigen DNA 1 Antigen DNA 2 Optional Immune modifie

  20. Slide 20: PLACCINE Bicistronic Vaccine Stronger Neutralizing Response than mRNA Benchmark

    PLACCINE-SARS-CoV-2 Bicistronic Vaccine Produces Stronger Neutralizing Immune Response than mRNA Benchmark • Vectors: pVac-15 (D614G); pVac-16 (Delta); pVac-17 (D614G-Delta) • 125 µg DNA • IgG titer (day 35) D614G variant Delta variant ns ns 4 4 ns ns ✱✱✱✱ ✱✱ 3 3 Titer IC50 Titer IC50 Titer r IC50 2

  21. Slide 21: Over 90% Protection From Live Viral Challenge

    Over 90% Protection From Live Viral Challenge Activity of PLACCINE-SARS-CoV-2 Vaccines in hACE2:K18 SARS-CoV-2 Model • pVac-15 (D614G) • pVac-16 (Delta) • pVac-17 (D614G-Delta) TCID50 Tissue Culture Infection Dose • 125 µg DNA D614G Challenge Delta Challenge TCID50 10 7 10 7 10 6 10 6 Viral Titer Vi

  22. Slide 22: Single Antigen PLACCINE Vaccine is Immunogenic in Cynomolgus Monkeys

    Single Antigen PLACCINE Vaccine is Immunogenic in Cynomolgus Monkeys 80% of PLACCINE Subjects Showed IgG Response • Single antigen vector pVac-15 (D614G) in CP-AlPO4 • Comparator mRNA Commercial mRNA Vaccine (LNP) • Dosing schedule Day 1, 28, 84 • IgG titers Day 105 (21 days after 3rd dose) 10 6 mRN

  23. Slide 23: Single Antigen PLACCINE Vaccine Cleared Viral Load of Cynomolgus Monkeys

    Single Antigen PLACCINE Vaccine Cleared Viral Load of Cynomolgus Monkeys Clearance efficiency comparable to mRNA vaccine by PCR assay : >99% clearance in every subject compared to average placebo control Nasal Swab Bronchoalveolar Lavage 10 9 10 9 (Day 2 after challenge) (day 2 after challenge) 10 8

  24. Slide 24: Single Antigen PLACCINE Vaccine Cleared Viral Load in Cynomolgus Monkeys

    Single Antigen PLACCINE Vaccine Cleared Viral Load in Cynomolgus Monkeys Clearance efficiency comparable to mRNA vaccine by PCR assay Nasal Swab Bronchoalveolar Lavage (Day 4 after challenge) 10 7 10 8 (day 4 after challenge) 10 7 10 6 10 6 10 5 Viral copies/ml viral copies/ml 10 5 10 4 10 4 10 3 10

  25. Slide 25: Durable Neutralizing Antibody Response to PLACCINE-SARS-CoV-2 Vaccines

    Durable Neutralizing Antibody Response to PLACCINE-SARS-CoV-2 Vaccines Evidence of Durability For Up To 5 Months (Ongoing Study) • Vectors: pVac-16 (Delta), pVac-17 (D614G -Delta) • 125 µg DNA • IgG titer (2, 3, 5 months) • Study: 22-002 4 nAB Assessment by a Delta Pseudo Lentivirus Assay 3 IC50 Tit

  26. Slide 26: Summary of Development Programs

    Summary of Development Programs GEN-1 offers a novel way to harness the PLACCINE SARS-CoV-2 Proof Concept has powerful immunological properties of demonstrated that our multicistronic IL-12: the “Master Switch” to the body’s formulated plasmid DNA platform can immune system. produce a robust immune

  27. Slide 27: Milestones & Financials

    Milestones & Financials © 2022 IMUNON Inc. PAGE 27

  28. Slide 28: Upcoming Key Milestones: Robust Flow of Value Creating Activities

    Upcoming Key Milestones: Robust Flow of Value Creating Activities GEN-1 OVATION 2 Initiation of GEN-1 OVATION 2 GEN-1 Initiation ORR & Surgical Data GEN-1 P2 Combo trial PFS Data of P3 in EOC with bevacizumab Interim results GEN-1 P2 Combo trial Initiation of with bevacizumab GEN-1 P1/2 Combo trial

  29. Slide 29: Strong Balance Sheet Supports Upcoming Milestones

    Strong Balance Sheet Supports Upcoming Milestones Cash Runway into 2025 Common shares outstanding Cash + Investments @ 6/30/2022 $48.1 million @ 6/30/2022 7.1 million + Stock Options 0.9 million Projected NOL sales – 2022-2024 + $3.5 million + Warrants 0.2 million Total $51.6 million Fully diluted s

  30. Slide 30: Corporate Information

    Corporate Information Headquarters Research Facility Princeton, NJ Huntsville, AL IMUNON 997 Lenox Drive, Suite 100 P 609-896-9100 www.imunon.com Lawrenceville, NJ 08648 F 609-896-2200 Nasdaq: IMNN © 2022 IMUNON Inc. PAGE 30

Imunon — Chardan's 6th Annual Genetic Medicines Conference 2022 on 6ix